Trump unveils pricing agreements with midsize biotech firms; Novartis halts CAR-T trial after patient deaths
read at raps ↗DealNeutral
The White House announced that President Trump has struck new pricing agreements with a group of midsize biotechnology companies, aiming to adjust drug costs.
Novartis disclosed that it is pausing its ongoing CAR-T cell therapy trial after several patient deaths were reported, citing safety concerns.
The combined news highlights both policy‑driven pricing initiatives and heightened regulatory scrutiny of advanced therapies, underscoring challenges for the sector.
source
This writeup was produced by pharmadog from original reporting by raps.
Original headline: “Recon: Trump announces new pricing deals with midsize biotechs; Novartis pauses CAR-T trials after patient deaths”
read at raps ↗72 words · retrieved Sep 2
comments(0)
5-min edit window · permanent after that